by Eric Christianson | Oct 16, 2024 | Infectious Disease and Oncology Medication and Disease State Clinical Pearls
Pivmecillinam, also known as Pivya, is an oral antibiotic that was FDA-approved in April of 2024 for use against uncomplicated urinary tract infections (UTI) in female patients.1 Pivmecillinam Literature Pivmecillinam falls in the class of penicillin antibiotics. It...
by Eric Christianson | Oct 13, 2024 | Endocrine Medication and Disease State Clinical Pearls
The American Thyroid Association defines hypothyroidism as a result of an “underactive thyroid gland.” Common symptoms include fatigue, cold sensitivity, dry skin, weight gain, hair loss, high cholesterol, or constipation. The recommended treatment is replacing the...
by Eric Christianson | Oct 9, 2024 | Gastrointestinal Medication and Disease State Clinical Pearls
Esophageal varices are large veins in the lower part of the esophagus that can be caused by portal hypertension which is a complication of liver disease. When stressed, these varices can rupture leading to excessive bleeding. The first line treatment for esophageal...
by Eric Christianson | Oct 6, 2024 | Clinical Pharmacy News and New Drug Updates, Women’s and Men’s Health Medication and Disease State Clinical Pearls
Fezolinetant (Veozah) is a central nervous system agent that works as an antagonist at the neurokinin 3 (NK3) receptor. This action inhibits neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neuron which alters activity in the thermoregulatory...
by Eric Christianson | Oct 2, 2024 | Clinical Pharmacy News and New Drug Updates
The FDA has been busy this year reviewing new medications. As a practicing pharmacist, it is hard to remember everything so I wanted to outline the top 5 drug approvals in 2024 that may impact ambulatory care and geriatrics. Without further ado, here’s my top 5...
